A federal judge in Illinois allowed a class action against Biogen Inc. to advance over the drugmaker’s alleged collusion with pharmacy benefit managers to favor its multiple sclerosis drug Tecfidera ...

CEO Chris Viehbacher told investors the company has worked to stabilize its business as its multiple sclerosis (MS) portfolio continues to decline, while building new growth drivers and reshaping its ...

June 16 (Reuters) - A drug approved to prevent rejection of transplanted kidneys significantly reduced relapses of multiple sclerosis in a late stage-trial sponsored by Biogen Idec and AbbVie Inc, but ...

Biogen now expects full-year adjusted earnings to come in at $15.75 to $16.25 per share, up from a previous forecast of $15 to $16 per share. The biotech company also expects 2024 sales to decline by ...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% year over year, beating the analyst consensus of $4.06. The company ...

Biogen has just launched a new app, called Aby, aimed at giving people living with multiple sclerosis (MS) accurate and reliable information about the condition and support. The app is free and gives ...